These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. A niche-like culture system allowing the maintenance of primary human acute myeloid leukemia-initiating cells: a new tool to decipher their chemoresistance and self-renewal mechanisms. Griessinger E; Anjos-Afonso F; Pizzitola I; Rouault-Pierre K; Vargaftig J; Taussig D; Gribben J; Lassailly F; Bonnet D Stem Cells Transl Med; 2014 Apr; 3(4):520-9. PubMed ID: 24493855 [TBL] [Abstract][Full Text] [Related]
28. Lack of noncanonical RAS mutations in cytogenetically normal acute myeloid leukemia. Reuter CW; Krauter J; Onono FO; Bunke T; Damm F; Thol F; Wagner K; Göhring G; Schlegelberger B; Heuser M; Ganser A; Morgan MA Ann Hematol; 2014 Jun; 93(6):977-82. PubMed ID: 24737308 [TBL] [Abstract][Full Text] [Related]
29. Pre-treatment with oral hydroxyurea prior to intensive chemotherapy improves early survival of patients with high hyperleukocytosis in acute myeloid leukemia. Mamez AC; Raffoux E; Chevret S; Lemiale V; Boissel N; Canet E; Schlemmer B; Dombret H; Azoulay E; Lengliné E Leuk Lymphoma; 2016 Oct; 57(10):2281-8. PubMed ID: 26849624 [TBL] [Abstract][Full Text] [Related]
30. Correlation of NPM1 Type A Mutation Burden With Clinical Status and Outcomes in Acute Myeloid Leukemia Patients With Mutated NPM1 Type A. Jo SY; Park SH; Kim IS; Yi J; Kim HH; Chang CL; Lee EY; Cho YU; Jang S; Park CJ; Chi HS Ann Lab Med; 2016 Sep; 36(5):399-404. PubMed ID: 27374703 [TBL] [Abstract][Full Text] [Related]
31. Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia. Chen X; Xie H; Wood BL; Walter RB; Pagel JM; Becker PS; Sandhu VK; Abkowitz JL; Appelbaum FR; Estey EH J Clin Oncol; 2015 Apr; 33(11):1258-64. PubMed ID: 25732155 [TBL] [Abstract][Full Text] [Related]
32. Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia. Shamaa S; Laimon N; Aladle DA; Azmy E; Elghannam DM; Salem DA; Taalab MM Hematology; 2014 Jan; 19(1):22-30. PubMed ID: 23540998 [TBL] [Abstract][Full Text] [Related]
33. Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997-2004). Veerman AJ; Kamps WA; van den Berg H; van den Berg E; Bökkerink JP; Bruin MC; van den Heuvel-Eibrink MM; Korbijn CM; Korthof ET; van der Pal K; Stijnen T; van Weel Sipman MH; van Weerden JF; van Wering ER; van der Does-van den Berg A; Lancet Oncol; 2009 Oct; 10(10):957-66. PubMed ID: 19747876 [TBL] [Abstract][Full Text] [Related]
35. Mutational spectrum and risk stratification of intermediate-risk acute myeloid leukemia patients based on next-generation sequencing. Wang B; Liu Y; Hou G; Wang L; Lv N; Xu Y; Xu Y; Wang X; Xuan Z; Jing Y; Li H; Jin X; Deng A; Wang L; Gao X; Dou L; Liang J; Chen C; Li Y; Yu L Oncotarget; 2016 May; 7(22):32065-78. PubMed ID: 27062340 [TBL] [Abstract][Full Text] [Related]
36. Clinical and prognostic implications of Roundabout 4 (robo4) in adult patients with acute myeloid leukemia. Chen YK; Hou HA; Tang JL; Jhuang JY; Lai YJ; Lee MC; Kuo YY; Chou WC; Liu CY; Lin CW; Chuang SS; Chen CY; Tseng MH; Huang CF; Chiang YC; Lee FY; Liu MC; Liu CW; Yao M; Huang SY; Ko BS; Hsu SC; Wu SJ; Tsay W; Chen YC; Tien HF PLoS One; 2015; 10(3):e0119831. PubMed ID: 25794001 [TBL] [Abstract][Full Text] [Related]
37. Allogeneic Stem Cell Transplantation Improves Survival in Patients with Acute Myeloid Leukemia Characterized by a High Allelic Ratio of Mutant FLT3-ITD. Ho AD; Schetelig J; Bochtler T; Schaich M; Schäfer-Eckart K; Hänel M; Rösler W; Einsele H; Kaufmann M; Serve H; Berdel WE; Stelljes M; Mayer J; Reichle A; Baldus CD; Schmitz N; Kramer M; Röllig C; Bornhäuser M; Thiede C; Ehninger G; Biol Blood Marrow Transplant; 2016 Mar; 22(3):462-9. PubMed ID: 26551637 [TBL] [Abstract][Full Text] [Related]
38. High-dose cytarabine as salvage therapy for relapsed or refractory acute myeloid leukemia--is more better or more of the same? Wolach O; Itchaki G; Bar-Natan M; Yeshurun M; Ram R; Herscovici C; Shpilberg O; Douer D; Tallman MS; Raanani P Hematol Oncol; 2016 Mar; 34(1):28-35. PubMed ID: 25689584 [TBL] [Abstract][Full Text] [Related]
39. Monosomal karyotype as an adverse prognostic factor in patients with acute myeloid leukemia treated with allogeneic hematopoietic stem-cell transplantation in first complete remission: a retrospective survey on behalf of the ALWP of the EBMT. Brands-Nijenhuis AV; Labopin M; Schouten HC; Volin L; Socié G; Cornelissen JJ; Huynh A; Ljungman P; Malard F; Esteve J; Nagler A; Mohty M Haematologica; 2016 Feb; 101(2):248-55. PubMed ID: 26589909 [TBL] [Abstract][Full Text] [Related]
40. Impact of early remission by induction therapy on allogeneic stem cell transplantation for acute myeloid leukemia with an intermediate-risk karyotype in first complete remission. Hemmati PG; Terwey TH; Na IK; le Coutre P; Jehn CF; Vuong LG; Dörken B; Arnold R Eur J Haematol; 2015 May; 94(5):431-8. PubMed ID: 25220715 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]